Ownership and insider activity for Xencor, Inc. (XNCR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders.
Price
| Price | $29.99 (closing price, October 28, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.5M | $16.5M | $26.2M | $50.3M | $163.5M | $143.5M | $53.9M | $53.8M | $40.9M | $54.1M |
| Short-term Investments | $115.6M | $207.6M | $268.1M | $476.8M | $439.5M | $190.6M | $569.1M | $539.9M | $456.9M | $493.7M |
| Receivables | $8.6M | $1.1M | $10.2M | $24.8M | $23.9M | $66.4M | $29.0M | $11.3M | $60.8M | $29.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $141.7M | $230.9M | $315.7M | $558.4M | $637.7M | $424.4M | $675.3M | $623.2M | $577.6M | $599.8M |
| Property, Plant & Equipment | $3.1M | $7.1M | $11.8M | $25.2M | $32.3M | $60.0M | $93.6M | $100.1M | $98.1M | $90.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $10.4M | $11.1M | $12.0M | $14.4M | $16.0M | $16.5M | $18.5M | $18.7M | $18.5M | $8.4M |
| Total Assets | $428.6M | $390.1M | $576.7M | $670.2M | $703.2M | $838.2M | $846.3M | $952.7M | $951.9M | $875.5M |
| Accounts Payable | $3.9M | $6.9M | $3.8M | $10.2M | $9.0M | $14.0M | $10.1M | $13.9M | $16.8M | $10.8M |
| Short-term Debt | 0 | 0 | 0 | $2.2M | 0 | 0 | 0 | $6.3M | $48.4M | $43.3M |
| Total Current Liabilities | $106.3M | $101.3M | $53.9M | $66.6M | $121.1M | $70.7M | $63.8M | $84.7M | $87.4M | $95.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $14.6M | $115.2M | $76.5M |
| Total Liabilities | $114.6M | $108.1M | $55.1M | $77.0M | $130.8M | $104.7M | $118.8M | $283.6M | $277.9M | $239.9M |
| Retained Earnings | -$238.0M | -$287.3M | -$323.3M | -$296.4M | -$365.7M | -$283.1M | -$338.3M | -$464.4M | -$704.0M | -$796.0M |
| Total Equity | $314.0M | $282.0M | $521.7M | $593.2M | $572.4M | $733.5M | $727.5M | $668.8M | $677.6M | $635.6M |
| Total Debt | 0 | 0 | 0 | $10.7M | $11.6M | $34.0M | $59.6M | $83.4M | $232.0M | $187.7M |
| Net Debt | -$130.1M | -$224.1M | -$294.4M | -$516.3M | -$591.4M | -$300.1M | -$563.4M | -$510.3M | -$265.8M | -$360.0M |
| Working Capital | $35.4M | $129.5M | $261.9M | $491.8M | $516.6M | $353.6M | $611.5M | $538.5M | $490.2M | $503.9M |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 6.39 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 1.73 |
Profitability
| Return on Equity | -28.66% |
| Return on Invested Capital | -33.40% |
| Return on Assets | -22.53% |
| Gross Margin | 43.31% |
| Operating Margin | -205.84% |
| Net Margin | -155.59% |
Related companies: GMAB · CLDX · NRIX · VRTX · 0QZU.L · 0R2M.L · MRNA · REGN
Explore sector: Healthcare · Biotechnology
More sections of XNCR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks